培美曲塞联合铂类化疗对晚期非小细胞肺癌患者外周血TGF-β1、MMP2的影响  

The changes of serum TGF-β1 and MMP-2 levels in advanced non-small cell lung cancer patients after pemetrexed combined with platinum chemotherapy

作　　者：李海丽[1] 王轶楠[1] 肖建波[1] 赵郁[1] 岳海淑[1] 王钧[1] 刘金慧[1] 

机构地区：[1]唐山市人民医院放化三科,河北唐山063001

出　　处：《现代肿瘤医学》2015年第23期3439-3442,共4页Journal of Modern Oncology

摘　　要：目的:观察培美曲塞联合铂类化疗对晚期非小细胞肺癌患者外周血TGF-β1、MMP2的影响及临床意义。方法:收集2011年1月至2012年12月,我院收治的50例选用培美曲塞联合铂类化疗的Ⅲ-Ⅳ期非小细胞肺癌患者外周血血清,用酶联免疫方法检测化疗前后外周血TGF-β1、MMP2表达水平,比较其动态变化;15例健康体检者为正常对照组。结果:健康者及肺癌患者外周血TGF-β1浓度分别为(9.62±2.70)μg/L、(41.56±7.54)μg/L,MMP2浓度分别为(44.47±11.47)μg/L、(101.60±16.43)μg/L(P<0.05),肺癌患者外周血TGF-β1、MMP2水平高于正常人。疾病控制组患者,化疗前后外周血TGF-β1浓度分别为(41.16±7.15)μg/L、(24.99±8.13)μg/L,MMP2浓度分别为(101.39±16.82)μg/L、(70.61±17.77)μg/L(P<0.05),差异均有统计学意义。疾病进展组患者化疗前后外周血TGF-β1浓度分别为(42.57±8.68)μg/L、(60.14±11.31)μg/L,MMP2浓度分别为(102.14±15.99)μg/L、(130.71±17.38)μg/L(P<0.05),差异均有统计学意义。结论:非小细胞肺癌患者外周血TGF-β1、MMP2的表达升高,疾病得到控制后TGF-β1、MMP2表达下降,而进展后升高。TGF-β1、MMP2可能是评价培美曲塞联合铂类化疗近期疗效的潜在指标。Objective： To investigate the serum levels of TGF-β1,MMP2 and its clinical significance after chemotherapy with pemetrexed and platinum in patients with advanced non-small cell lung cancer. Methods： All 50 cases of Ⅲ-Ⅳ non-small cell lung cancer patients with pemetrexed and platinum chemotherapy were selected. The levels of serum TGF-β1 and MMP2 were detected by ELISA. Results： The serum levels of TGF-β1 were（ 9. 62 ± 2. 70）μg /L,（ 41. 56 ± 7. 54） μg /L,in control group and NSCLC group respectively,and MMP2 was（ 44. 47 ± 11. 47） μg /L,（ 101. 60 ± 16. 43） μg / L respectively（ P〈0. 05）. The serum levels of TGF-β1 and MMP2 in NSCLC patients were higher than that of control group. In disease control group,the contents of TGF-β1 was（ 41. 16 ± 7. 15） μg / L,（ 24. 99 ± 8. 13） μg/L before and after chemotherapy respectively and MMP2 was（ 101. 39 ± 16. 82） μg/L,（ 70. 61 ±17. 77） μg / L,respectively（ P〈0. 05）. In disease progressive group,the contents of TGF-β1 was（ 42. 57 ± 8. 68）μg /L,（ 60. 14 ± 11. 31） μg /L before and after chemotherapy respectively and MMP2 was（ 102. 14 ± 15. 99） μg /L,（ 130. 71 ± 17. 38） μg/L（ P〈0. 05）. Conclusion： Serum levels of TGF-β1 and MMP2 in NSCLC patients were higher. It decreased when the disease was controlled and it was increased at the time of disease progression. The serum levels of TGF-β1 and MMP2 may be potential biomarkers to evaluate the short-time efficancy of pemetrexed combined with platinum based chemotherapy.

关 键 词：非小细胞肺癌 转化生长因子Β1 基质金属蛋白酶2 

分 类 号：R734.2[医药卫生—肿瘤]